Oral Contraceptives and Inherited Thrombophilia: A Gene-Environment Interaction with a Risk of Venous Thrombosis?

Melvin R. Mac Gillavry; Martin H. Prins

doi:10.1055/s-2003-38838

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2003; 29(2): 219-226
DOI: 10.1055/s-2003-38838

Oral Contraceptives and Inherited Thrombophilia: A Gene-Environment Interaction with a Risk of Venous Thrombosis?

Melvin R. Mac Gillavry¹ , Martin H. Prins²

¹Physician, Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
²Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht, University of Maastricht, Maastricht, The Netherlands

Abstract

ABSTRACT

There are indications in the literature that asymptomatic women with an inherited thrombophilic defect who use oral contraceptive have an increased risk of venous thrombosis. There are no consistent data regarding the thrombotic risk in users of oral contraceptives with an inherited thrombophilic defect and personal history of venous thrombosis. Selective genetic screening on the basis of clinical judgment, and family and personal history, instead of universal screening, may be useful before oral contraceptives are prescribed. Nonetheless, the actual risks and benefits of such practice remain to be examined.

KEYWORDS

Thrombophilia - oral contraceptives - venous thrombosis - screening

Volltext

Referenzen

REFERENCES

1 Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet . 1993; 353 1167-1173
2 van Boven H H, Vandenbroucke J P, Briët E, Rosendaal F R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood . 1999; 8 2590-2594
3 Heijboer H, Brandjes D PM, Büller H R, Sturk A, ten Cate W J. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med . 1990; 323 1512-1516
4 Koster T, Rosendaal F R, Briët E. et al . Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood . 1995; 85 2756-2761
5 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA . 1993; 90 1004-1008
6 Bertina R M, Koeleman B PC, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
7 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
8 Stampfer M J, Malinow M R, Willett W C. et al . A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA . 1992; 268 877-881
9 Falcon C R, Cattaneo M, Panzeri D, Martinelli I, Mannucci P M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb . 1994; 14 1080-1083
10 den Heijer M, Blom H J, Gerrits W B. et al . Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?. Lancet . 1995; 345 882-885
11 Fermo I, Vigano' D S, Paroni R. et al . Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med . 1995; 123 747-753
12 den Heijer M, Koster T, Blom H J. et al . Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med . 1996; 334 759-762
13 Simioni P, Prandoni P, Burlina A. et al . Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost . 1996; 76 883-886
14 Koster T, Blann A D, Briët E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII and effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet . 1995; 345 152-155
15 Kraaijenhagen R A, in't Anker S P, Koopman M M. et al . High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost . 2000; 83 5-9
16 Vandenbroucke J P, Koster T, Briët E. et al . Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet . 1994; 344 1453-1457
17 Bloemenkamp K WM, Rosendaal F R, Büller H R. et al . Enhancement by factor V Leiden of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet . 1995; 346 1593-1596
18 Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med . 1992; 232 155-160
19 Anderson F A, Wheeler H B, Goldberg R J. et al . A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med . 1991; 151 933-938
20 Vandenbroucke J P, van der Meer J M F, Helmerhorst F M, RosendaalFR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ . 1996; 313 1127-1130
21 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
22 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA . 1997; 277 1305-1307
23 Rosendaal F R, Doggen C J, Zivelin A. et al . Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost . 1998; 79 706-708
24 Tait R C, Walker I D, Perry D J. et al . Prevalence of antithrombin deficiency in the healthy population. Br J Haematol . 1994; 87 106-112
25 Tait R C, Walker I D, Reitsma P H. et al . Prevalence of protein C deficiency in the healthy population. Thromb Haemost . 1995; 73 87-93
26 Pabinger I, Brucker S, Kyrle P A. et al . Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis . 1992; 3 547-553
27 Cumming A M, Keeney S, Salden A. et al . The prothrombin gene G20210A variant: prevalence in a U.K anticoagulant clinic population. Br J Haematol . 1997; 98 353-355
28 Gladson C L, Scharrer I, Hach V, Beck K H, Griffin J H. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost . 1988; 59 18-22
29 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost . 1989; 61 50-54
30 Schattner A, Kasher I, Berrebi A. Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years. QJM . 1998; 90 283-287
31 Allaart C F, Poort S R, Rosendaal F R. et al . Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet . 1993; 341 134-138
32 van den Belt G M A, Prins M H, Huisman M V, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost . 1996; 2 227-236
33 Simioni P, Sanson B J, Prandoni P. et al . Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost . 1999; 81 198-202
34 Pabinger I, Kyrle P A, Heistinger M. et al . The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost . 1994; 71 441-445
35 Sanson B J, Simioni P, Prins M H, on behalf of the TACT-study group. The incidence of venous thromboembolism in asymtomatic carriers of a marker of thrombophilia. Blood . 1999; 94 3702-3706
36 De Stefano V, Leone G, Mastrangelo S. et al . Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost . 1994; 72 352-358
37 van den Belt G M A, Sanson B J, Simioni P. et al . Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med . 1997; 157 2227-2232
38 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet . 1993; 342 1503-1506
39 Ridker P M, Hennekens C H, Lindpainter K. et al . Mutation in the gene encoding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med . 1995; 332 912-917
40 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol . 1997; 98 907-909
41 Middeldorp S, Henkens C MA, Koopman M MW. et al . The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med . 1998; 128 15-20
42 Ridker P M, Glynn R J, Miletich J P. et al . Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med . 1997; 126 528-531
43 Middeldorp S, Meinardi J R, Koopman M MW. et al . A prospective study on the incidence of clinically overt venous thromboembolism in asymptomatic carriers of the FV:Q506 mutation (Abst). Thromb Haemost . 1999; 82 418
44 Simioni P, Prandoni P, Girolami A. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation (letter). Ann Intern Med . 1999; 130 538
45 Middeldorp S, Meinardi J R, van Thienen V J. et al . The incidence of venous thromboembolism in relatives of patients with the prothrombin 20210A mutation (Abst). Thromb Haemost . 1999; 82 277
46 Ridker P M, Miletich J P, Stampfer M J. et al . Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation . 1995; 92 2800-2802
47 Simioni P, Prandoni P, Lensing A W. et al . The risk of recurrent venous thromboembolism in patients with an Arg506/ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med . 1997; 336 399-403
48 Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost . 1996; 75 229-232
49 Eichinger S, Pabinger I, Stümpflen A. et al . The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost . 1997; 77 624-628
50 Eichinger S, Minar E, Hirschl M. et al . The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost . 1999; 81 14-17
51 O'Donnell J, Tuddenham E G, Manning R. et al . High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase protein. Thromb Haemost . 1997; 77 825-828
52 Eichinger S, Stümpflen A, Hirschl M. et al . Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost . 1998; 80 566-569
53 Kyrle P A, Minar E, Hirschl M. et al . High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med . 2000; 343 457-462
54 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet . 1995; 346 1575-1582
55 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet . 1995; 346 1589-1593
56 Lewis M A, Heinemann L AJ, MacRae K D, Bruppacher R, Spitzer W O. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research (erratum: Contraception 1996;54:121). Contraception . 1996; 54 5-13
57 Spitzer W O, Lewis M A, Heinemann L J, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ . 1996; 312 83-88
58 Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception . 1998; 57 291-301
59 Vasilakis C, Jick S S, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception . 1999; 59 79-83
60 Parkin L, Skegg D CG, Wilson M, Herbison G P, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet . 2000; 355 2133-2134
61 Bloemenkamp K WM, Rosendaal F R, Büller H R. et al . Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med . 1999; 159 65-70
62 Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med . 1998; 244 27-32
63 Andersen B S, Olsen J, Nielsen G L. et al . Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism. Thromb Haemost . 1998; 79 23-31
64 Herings R MC, Urquhart J, Leufkens H GM. Venous thromboembolism among new users of different oral contraceptives (Erratum: Lancet 1999;354:1478). Lancet . 1999; 354 127-128
65 Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet . 1999; 354 1610-1611
66 Burnhill M S. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil Womens Med . 1999; 44 19-30
67 Farmer R DT, Lawrenson R A, Thompson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet . 1997; 349 83-88
68 Farmer R DT, Todd J C, MacRae K D, Williams T J, Lewis M A. Oral contraception was not associated with venous thromboembolic disease in recent study. BMJ . 1998; 316 1090
69 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol . 1999; 19 700-703
70 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med . 2000; 160 49-52
71 Spannagl M, Heinemann L AJ, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?. Eur J Contracept Reprod Health Care . 2000; 5 105-112
72 Bloemenkamp K WM, Helmerhorst F M, Rosendaal F RR, Vandenbroucke J P. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost . 1999; 82 1024-1027
73 Creinin M D, Lisman R, Strickler R C. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril . 1999; 72 646-651
74 Palareti G, Legnani C, Frascaro M. et al . Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. Contraception . 1999; 59 293-299
75 Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ . 2001; 322 1024-1025